A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 19, 2022

Primary Completion Date

November 27, 2023

Study Completion Date

March 6, 2026

Conditions
Cardiomyopathy, Hypertrophic Obstructive
Interventions
DRUG

Mavacamten

Specified dose on specified days

Trial Locations (20)

1830003

Local Institution - 0003, Fuchu-Shi

798-8510

Local Institution - 0020, Uwajima

672-8044

Local Institution - 0026, Himeji-Shi

650-0047

Local Institution - 0016, Kobe

305-0005

Local Institution - 0017, Tsukuba

920-8641

Local Institution - 0023, Kanazawa

227-8501

Local Institution - 0019, Yokohama

783-8505

Local Institution - 0015, Nankoku-shi

514-0001

Local Institution - 0028, Tsu

980-8574

Local Institution - 0027, Sendai

564-8565

Local Institution - 0014, Suita

565-0871

Local Institution - 0011, Suita-Shi

431-3192

Local Institution - 0012, Hamamatsu

113-0033

Local Institution - 0010, Bunkyo-Ku

104-0044

Local Institution - 0009, Chuo-Ku

173-0003

Local Institution - 0001, Itabashi-Ku

135-0061

Local Institution - 0007, Koto-Ku

160-8582

Local Institution - 0005, Shinjuku-Ku

162-8666

Local Institution - 0013, Shinjuku-ku

558-8558

Local Institution - 0018, Osaka

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05414175 - A Study of Mavacamten in Obstructive Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter